-logo-1200x675.png?v=20220915161652&w=240&h=240&zc=2){kind=logo}
Barclays Has Lowered Expectations for Intellia Therapeutics (NASDAQ:NTLA) Stock Price
Intellia Therapeutics (NASDAQ:NTLA – Free Report) had its target price reduced by Barclays from $55.00 to $26.00 in a report published on Friday,Benzinga reports. Barclays currently has an overweight rating on the stock. Several other brokerages also recently weighed in on NTLA. Morgan Stanley downgraded shares of Intellia Therapeutics from an “overweight” rating to an […]
Intellia Therapeutics (NASDAQ:NTLA – Free Report) had its target price reduced by Barclays from $55.00 to $26.00 in a report published on Friday,Benzinga reports. Barclays currently has an overweight rating on the stock. Several other brokerages also recently weighed in on NTLA. Morgan Stanley downgraded shares of Intellia Therapeutics from an “overweight” rating to an […]
